Samjin Pharmaceutical Co., Ltd. Statistics
Want to see KR:005500 full AI Analyst Report?
Samjin Pharmaceutical Co., Ltd. (005500) Stock Statistics & Valuation Metrics
Total Valuation
Samjin Pharmaceutical Co., Ltd. has a market cap or net worth of KRW 236.21B. The enterprise value is KRW 347.35B.
- Market Cap
- KRW 236.21B
- Enterprise Value
- KRW 347.35B
Share Statistics
Samjin Pharmaceutical Co., Ltd. has 13,320,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,320,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.89%
Financial Efficiency
Samjin Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 5.73%.
- Return on Equity (ROE)
- 0.08
- Return on Assets (ROA)
- 0.05
- Return on Invested Capital (ROIC)
- 5.73%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 377.45M
- Profits Per Employee
- 29.51M
- Employee Count
- 819
- Asset Turnover
- 0.66
- Inventory Turnover
- 1.41
Valuation Ratios
The current PE Ratio of Samjin Pharmaceutical Co., Ltd. is 9.06. Samjin Pharmaceutical Co., Ltd.’s PEG ratio is 0.54.
- PE Ratio
- 9.06
- PS Ratio
- 0.69
- PB Ratio
- 0.72
- Price to FCF
- 8.27
- Price to Operating Cash Flow
- 6.34
- PEG Ratio
- 0.54
Income Statement
In the last 12 months, Samjin Pharmaceutical Co., Ltd. had revenue of 309.13B and earned 24.17B in profits. Earnings per share was 1962.68.
- Revenue
- 309.13B
- Gross Profit
- 153.03B
- Operating Income
- 24.68B
- Pretax Income
- 22.10B
- Net Income
- 24.17B
- EBITDA
- 44.50B
- Earnings Per Share (EPS)
- 1962.68
Cash Flow
In the last 12 months, operating cash flow was 33.83B and capital expenditures -7.90B, giving a free cash flow of 25.92B billion.
- Operating Cash Flow
- 33.83B
- Free Cash Flow
- 25.92B
- Free Cash Flow per Share
- 2048.01
Dividends & Yields
Samjin Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 3.97%
- Dividend Per Share
- ―
- Dividend Yield
- 3.97%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 12.09%
- Earnings Yield
- 10.85%
Stock Price Statistics
- Beta
- 0.05
- 52-Week Price Change
- -15.51%
- 50-Day Moving Average
- 19237.80
- 200-Day Moving Average
- 18892.30
- Relative Strength Index (RSI)
- 57.32
- Average Volume (3m)
- 41.43K
Important Dates
Samjin Pharmaceutical Co., Ltd. upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 16, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Samjin Pharmaceutical Co., Ltd. as a current ratio of 1.30, with Debt / Equity ratio of 46.80%
- Current Ratio
- 1.30
- Quick Ratio
- 0.55
- Debt to Market Cap
- 0.56
- Net Debt to EBITDA
- 2.78
- Interest Coverage Ratio
- 4.99
Taxes
In the past 12 months, Samjin Pharmaceutical Co., Ltd. has paid -2.07B in taxes.
- Income Tax
- -2.07B
- Effective Tax Rate
- -0.09
Enterprise Valuation
Samjin Pharmaceutical Co., Ltd. EV to EBITDA ratio is 17.31, with an EV/FCF ratio of 12.79.
- EV to Sales
- 1.06
- EV to EBITDA
- 17.31
- EV to Free Cash Flow
- 12.79
- EV to Operating Cash Flow
- 9.80
Balance Sheet
Samjin Pharmaceutical Co., Ltd. has KRW 20.88B in cash and marketable securities with KRW 129.88B in debt, giving a net cash position of -KRW 109.01B billion.
- Cash & Marketable Securities
- KRW 20.88B
- Total Debt
- KRW 129.88B
- Net Cash
- -KRW 109.01B
- Net Cash Per Share
- -KRW 8,183.73
- Tangible Book Value Per Share
- KRW 21.99K
Margins
Gross margin is 45.63%, with operating margin of 6.74%, and net profit margin of 7.47%.
- Gross Margin
- 45.63%
- Operating Margin
- 6.74%
- Pretax Margin
- 7.62%
- Net Profit Margin
- 7.47%
- EBITDA Margin
- 6.15%
- EBIT Margin
- -0.65%
Analyst Forecast
The average price target for Samjin Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 0.28%
- EPS Growth Forecast
- 16.80%
Scores
- Smart Score
- ―
- AI Score
- 62

